Clinical Trials | December 24, 2025
Neurocrine’s Valbenazine fails to show benefit in largest dyskinetic cerebral palsy trial
Adverse events were consistent with valbenazine’s established safety profile
Adverse events were consistent with valbenazine’s established safety profile
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
Deceased donor kidney transplants are time-critical, and it is uncommon to attempt them robotically
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
This innovation reinforces Fredun's commitment to creating a 360 degree pet wellness ecosystem
Early stage projects of up to Rs. 9 crore eligible for up to Rs. 5 crore assistance and later stage projects of up to Rs. 285 crore eligible for up to Rs. 100 crore assistance
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
The pet dog population alone is expected to increase from 21.4 million in 2019 to 51.5 million by 2028
Acquisition to be followed by merger; strengthens Torrent’s IPM market presence
Subscribe To Our Newsletter & Stay Updated
